Sarepta Therapeutics (SRPT) Defended at Citi After Shares Drop 12% in 2 Days
Tweet Send to a Friend
Citi analyst Joel Beatty reiterated a Buy rating and $177.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) with shares down ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
